Biochem Pharma (BCHE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jean-Robert Grenier who wrote (458)	10/4/1998 3:13:00 PM
From: Richard Haugland	Read Replies (2) of 783

*OFF TOPIC -- AETERNA* A press release in the Sept 15 Genetic Engineering News is as follows: (edited) Aeterna Labs has isolated a new molecule of low molecular weight that could be the key to a new class of drugs for treating diseases complicated by angiogenesis, including cancer, psoriasis and arthritis. The molecule has matrix metalloprotease (MMP) inhibition properties ... MMP enzymes work by destroying the interstitial net between cells, thus opening spaces for cancer growth. Cancers produce large quantities of MMPs as they develop, The new discovery is part of the company's ongoing programs for characterizing its angiogenesis inhibitor, AE-941, a product currently undergoing clinical studies ... obviously in very early studies Unfortunately, a big day for this stock is when it trades ANY shares and it seems to be able to go for a month or months at a time with almost no trades. quote.yahoo.com Also, being on the Toronto exchange, there is a derth of financial information on the company. Yahoo says it lost 3 cents a share this year but I don't even know how many shares it has. Apparently only one trade since its announcement on September 15 and that was 3000 shares down about 20% from its previous trade.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next